Bufalin induces the apoptosis of acute promyelocytic leukemia cells via the downregulation of survivin expression

Acta Haematologica

Volumn 128, Issue 3, 2012, Pages 144-150

  Zhu, Zhitu ^a   Li, Enze ^a   Liu, Yangyang ^a   Gao, Yu ^a   Sun, Hongzhi ^a   Wang, Ying ^a   Wang, Zhenghua ^a   Liu, Xiaomei ^a   Wang, Qingjun ^a   Liu, Yunpeng ^b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; Apoptosis; Bufalin; Caspase; Survivin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BUFALIN; CASPASE 3; SURVIVIN;

APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

APOPTOSIS; BUFANOLIDES; CASPASE 3; CELL PROLIFERATION; DOWN-REGULATION; ENZYME ACTIVATION; FLAVONOIDS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASTIC CELLS, CIRCULATING;

EID: 84864812699     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000339424     Document Type: Article

References (12)

1. Reiter A, Lengfelder E, Grimwade D: Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia. Acta Haematol 2004; 112: 55-67.
2. Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, Cao YX, Yi Y, Yang JJ, Peng HL, Zhong HY, Li RJ: Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol 2009; 121: 1-8.
3. Kamimura T, Miyamoto T, Harada M, Akashi K: Advances in therapies for acute promyelocytic leukemia. Cancer Sci 2011; 102: 1929-1937.
4. Cilloni D, Frassoni F, Saglio G: Emerging targets for hematological malignancies. Curr Opin Drug Discov Devel 2010; 13: 548-558.
5. Liang QL, Wang BR, Li GH: DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 2009; 10: 675-682.
6. Esh AM, Atfy M, Azizi NA, El Naggar MM, Khalil EE, Sherief L: Prognostic significance of survivin in pediatric acute lymphoblastic leukemia. Indian J Hematol Blood Transfus 2011; 27: 18-25.
7. Chen A, Yu J, Zhang L, Sun Y, Zhang Y, Guo H, Zhou Y, Mitchelson K, Cheng J: Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett 2009; 31: 487-494.
8. Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH: Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia 2011; 26: 623-632.
9. Sanna MG, da Silva Correia J, Ducrey O, Lee J, Nomoto K, Schrantz N, Deveraux QL, Ulevitch RJ: IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol Cell Biol 2002; 22: 1754-1766.
10. Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-4679.
11. Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG: Novel targets in solid tumors: MEK inhibitors. Clin Adv Hematol Oncol 2006; 4: 831-836.
12. Barbarroja N, Siendones E, Torres LA, Luque MJ, Martinez JM, Dorado G, Velasco F, Torres A, López-Pedrera C: MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia. Br J Haematol 2008; 142: 27-35.